CMS implements Inflation Reduction Act payment increase for qualifying biosimilars

Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.
Related News Articles
Headline
The Federal Communications Commission today released a final rule adopting changes proposed last year to the Rural Health Care Program to improve the…
Headline
Deceptively branded as an effort to save the 340B program, a legislative campaign by the Pharmaceutical Research and Manufacturers of America, National…
Headline
The Centers for Medicare & Medicaid Services today instructed certified independent dispute resolution entities to resume making payment determinations for…
Headline
Quality improvement initiatives create “a living, breathing network of providers and patients working together to achieve optimal outcomes for all communities…
Blog
The values of rural America mirror those of health care quality: people first. The challenge of delivering equitable, effective care is particularly acute in…
Chairperson's File
On this episode, I talk with Jennifer Havens, CEO of UnityPoint Health – Grinnell Regional Medical Center, a 49-bed hospital serving several counties in Iowa…